Vitria Adisetiyo1, Jens H Jensen, Ali Tabesh, Rachael L Deardorff, Els Fieremans, Adriana Di Martino, Kevin M Gray, Francisco X Castellanos, Joseph A Helpern. 1. From the Center for Biomedical Imaging (V.A., J.H.J., A.T., R.L.D., J.A.H.), Department of Radiology and Radiological Science (V.A., J.H.J., A.T., R.L.D., J.A.H.), Department of Psychiatry and Behavioral Sciences (K.M.G.), and Department of Neurosciences (J.A.H.), Medical University of South Carolina, 68 President St, Bioengineering Building, 2nd Floor, Charleston, SC 29425; Center for Biomedical Imaging, Department of Radiology (E.F., F.X.C.), Child Study Center, Department of Child and Adolescent Psychiatry (A.D.M., F.X.C.), and Department of Physiology and Neuroscience (F.X.C.), New York University School of Medicine, New York, NY; and Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY (F.X.C.).
Abstract
PURPOSE: To comprehensively assess brain iron levels in typically developing control subjects and patients with attention deficit hyperactivity disorder (ADHD) when psychostimulant medication history is accounted for. MATERIALS AND METHODS: This prospective study was approved by the institutional review board, and informed consent was obtained. Brain iron was indexed noninvasively by using magnetic resonance (MR) imaging relaxation rates (R2, R2*, R2') and magnetic field correlation (MFC) in the globus pallidus, putamen, caudate nucleus, and thalamus for 22 patients with ADHD (12 medication-naïve patients and 10 with a history of psychostimulant treatment) and 27 control subjects (age range, 8-18 years). Serum iron measures were also collected. Subgroup differences were analyzed with data-appropriate omnibus tests followed by post hoc pairwise comparisons; false discovery rate correction was conducted to control for multiple comparisons. RESULTS: Medication-naïve ADHD patients had significantly lower striatal and thalamic MFC indexes of brain iron than did control subjects (putamen, P = .012; caudate nucleus, P = .008; thalamus, P = .012) and psychostimulant-medicated ADHD patients (putamen, P = .006; caudate nucleus, P = .010; thalamus, P = .021). Conversely, the MFC indexes in medicated patients were comparable to those in control subjects. No significant differences were detected with R2, R2*, R2', or serum measures. CONCLUSION: Lower MFC indexes of striatal and thalamic brain iron in medication-naïve ADHD patients and lack of differences in psychostimulant-medicated patients suggest that MFC indexes of brain iron may represent a noninvasive diagnostic biomarker that responds to psychostimulant treatment.
PURPOSE: To comprehensively assess brain iron levels in typically developing control subjects and patients with attention deficit hyperactivity disorder (ADHD) when psychostimulant medication history is accounted for. MATERIALS AND METHODS: This prospective study was approved by the institutional review board, and informed consent was obtained. Brain iron was indexed noninvasively by using magnetic resonance (MR) imaging relaxation rates (R2, R2*, R2') and magnetic field correlation (MFC) in the globus pallidus, putamen, caudate nucleus, and thalamus for 22 patients with ADHD (12 medication-naïve patients and 10 with a history of psychostimulant treatment) and 27 control subjects (age range, 8-18 years). Serum iron measures were also collected. Subgroup differences were analyzed with data-appropriate omnibus tests followed by post hoc pairwise comparisons; false discovery rate correction was conducted to control for multiple comparisons. RESULTS: Medication-naïve ADHDpatients had significantly lower striatal and thalamic MFC indexes of brain iron than did control subjects (putamen, P = .012; caudate nucleus, P = .008; thalamus, P = .012) and psychostimulant-medicated ADHDpatients (putamen, P = .006; caudate nucleus, P = .010; thalamus, P = .021). Conversely, the MFC indexes in medicated patients were comparable to those in control subjects. No significant differences were detected with R2, R2*, R2', or serum measures. CONCLUSION: Lower MFC indexes of striatal and thalamic brain iron in medication-naïve ADHDpatients and lack of differences in psychostimulant-medicated patients suggest that MFC indexes of brain iron may represent a noninvasive diagnostic biomarker that responds to psychostimulant treatment.
Authors: E Mark Haacke; Norman Y C Cheng; Michael J House; Qiang Liu; Jaladhar Neelavalli; Robert J Ogg; Asadullah Khan; Muhammad Ayaz; Wolff Kirsch; Andre Obenaus Journal: Magn Reson Imaging Date: 2005-01 Impact factor: 2.546
Authors: Eve M Dumas; Maarten J Versluis; Simon J A van den Bogaard; Matthias J P van Osch; Ellen P Hart; Willeke M C van Roon-Mom; Mark A van Buchem; Andrew G Webb; Jeroen van der Grond; Raymund A C Roos Journal: Neuroimage Date: 2012-03-28 Impact factor: 6.556
Authors: Nora D Volkow; Gene-Jack Wang; Scott H Kollins; Tim L Wigal; Jeffrey H Newcorn; Frank Telang; Joanna S Fowler; Wei Zhu; Jean Logan; Yeming Ma; Kith Pradhan; Christopher Wong; James M Swanson Journal: JAMA Date: 2009-09-09 Impact factor: 56.272
Authors: Alice Egerton; Mitul A Mehta; Andrew J Montgomery; Julia M Lappin; Oliver D Howes; Suzanne J Reeves; Vincent J Cunningham; Paul M Grasby Journal: Neurosci Biobehav Rev Date: 2009-05-27 Impact factor: 8.989
Authors: Jens H Jensen; Kamila Szulc; Caixia Hu; Anita Ramani; Hanzhang Lu; Liang Xuan; Maria F Falangola; Ramesh Chandra; Edmond A Knopp; John Schenck; Earl A Zimmerman; Joseph A Helpern Journal: Magn Reson Med Date: 2009-02 Impact factor: 4.668
Authors: Staffan K Berglund; Anna Chmielewska; Josefine Starnberg; Björn Westrup; Bruno Hägglöf; Mikael Norman; Magnus Domellöf Journal: Pediatr Res Date: 2017-10-25 Impact factor: 3.756
Authors: Arjun Sethi; Edwin Evelyn-Rahr; Nicholas Dowell; Sanjay Jain; Valerie Voon; Hugo D Critchley; Neil A Harrison; Mara Cercignani Journal: Neuroimage Clin Date: 2017-03-30 Impact factor: 4.881